Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas

Melanoma Research

Volumn 8, Issue 6, 1998, Pages 504-509

  Kroiss, M M ^a   Bosserhoff, A K ^a   Vogt, T ^a   Buettner, R ^a   Bogenrieder, T ^a   Landthaler, M ^a   Stolz, W ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Malignant melanoma; P53; P73; Tumour suppressor

Indexed keywords

DNA; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CANCER; SKIN CARCINOGENESIS; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

EID: 0032432810     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199812000-00005     Document Type: Article

References (26)

1. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferraras P, McKeon F, Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.
2. Bale SJ, Dracopoli NC, Tucker MA, Clark WH jr, Fraser MC, Stanger BZ, Green P, Donis-Keller H, Housman DE, Green MH. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320: 1367-1372.
3. van Haeringen A, Bergman W, Nelen MR, van der Kooij-Meijs E, Hendrikse I, Wijnen JT, Khan PM, Klasen EC, Frants RR. Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families. Genomics 1989; 5: 61-64.
4. Gruis NA, Bergman W, Frants RR. Locus for susceptibility to melanoma on chromosome 1p. N Engl J Med 1990; 322: 853-855.
5. Cannon-Albright LA, Goldgar DE, Wright EC, Turco A, Jost M, Meyer LJ, Piepkorn M, Zone JJ, Skolnick MH. Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. Am J Hum Genet 1990; 46: 912-918.
6. Kefford RF, Salmon J, Shaw HM, Donald JA, McCarthy WH. Hereditary melanoma in Australia: variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 1991; 51: 45-55.
7. Fountain JW, Karayiorgou M, Graw SL, Buckler AJ, Taruscio D, Ward DC, Ernstoff MS, Kirkwood JM, Andersen LB, Collins FS, Dracopoli NC, Housman DE. Chromosome 9p involvement in melanoma. Am J Hum Genet 1991; 49: A45.
8. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian V, Stockert E, Day RS, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
9. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olufunmilayo IO, Diaz MO, Kwiatkowski DJ, Piepkorn MW, Zone JJ, Skolnick MH. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258: 1148-1152.
10. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338: 879-887.
11. Reed JA, Loganzo F Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713-2718.
12. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997; 74: 255-259.
13. Chang TG, Wang J, Chen LW, Hsu CY, Chang HW, Chen JS, Cho CL. Loss of expression of the p16 gene is frequent in malignant skin tumors. Biochem Biophys Res Commun 1997; 230: 85-88.
14. Wang YL, Uhara H, Yamazaki Y, Nikaido T, Saida T. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br J Dermatol 1996; 134: 269-275.
15. Volkenandt M, Schlegel U, Nanus DM, Albino AP Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 1991; 4: 35-40.
16. Akslen LA, Monstad SE, Larsen B, Straume O, Ogreid-D. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer 1998; 79: 91-95.
17. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris-AL. Expression of mutant p53 in melanoma. Cancer Res 1991; 51: 5976-5979.
18. Vogt T, Zipperer KH, Vogt A, Hölzel D, Landthaler M, Stolz W. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997; 30: 57-63.
19. Jost CA, Marin MC, Kaelin WG Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389: 191-194.
20. Sunahara M, Ichimiya S, Nimura Y, Takada N, Sakiyama S, Sato Y, Todo S, Adachi W, Amano J, Nakagawara A. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int J Oncol 1998; 13: 319-323.
21. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI, Liu W. Activation of p73 silent allele in lung cancer. Cancer Res 1998; 58: 2347-2349.
22. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998; 58: 2076-2077.
23. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T, Takahashi T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998; 58: 1380-1383
24. McClelland M, Mathieu-Daude F, Welsh J. RNA finger-printing and differential display using arbitrarily primed PCR. Trends Genet 1995; 11: 242-246.
25. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
26. Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, Friedman P, Prives C, Vogelstein B. Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 1991; 6: 131-136.